GSK-BEL112234

Study Sponsor: GSK

Study Title

A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects with Systemic Lupus Erythematosus (SLE) who completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057

Medicine or Vaccine (generic name)

belimumab

Sponsor Identification Number

BEL112234

Trial Registry Identification Number(#'s)

NCT00712933 2007-007648-85

Medical Condition

Systemic Lupus Erythematosus

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=112234

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00712933

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2007-007648-85

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This is a follow-up study to HGS1006-C1056 and HGS1006-C1057. This study is available in CDISC format.

Date Added to this Site

September 2019